Abstract
Doxorubicin, the most prescribed chemotherapeutic drug, causes dose-dependent cardiotoxicity and heart failure. However, our understanding of the immune response elicited by doxorubicin is limited. Here we show that an aberrant CD8+ T cell immune response following doxorubicin-induced cardiac injury drives adverse remodeling and cardiomyopathy. Doxorubicin treatment in non-tumor-bearing mice increased circulating and cardiac IFNγ+CD8+ T cells and activated effector CD8+ T cells in lymphoid tissues. Moreover, doxorubicin promoted cardiac CD8+ T cell infiltration and depletion of CD8+ T cells in doxorubicin-treated mice decreased cardiac fibrosis and improved systolic function. Doxorubicin treatment induced ICAM-1 expression by cardiac fibroblasts resulting in enhanced CD8+ T cell adhesion and transformation, contact-dependent CD8+ degranulation and release of granzyme B. Canine lymphoma patients and human patients with hematopoietic malignancies showed increased circulating CD8+ T cells after doxorubicin treatment. In human cancer patients, T cells expressed IFNγ and CXCR3, and plasma levels of the CXCR3 ligands CXCL9 and CXCL10 correlated with decreased systolic function.
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
MeSH terms
-
Animals
-
Antibiotics, Antineoplastic / adverse effects
-
Antibiotics, Antineoplastic / toxicity
-
Cardiomyopathies / chemically induced
-
Cardiomyopathies / immunology
-
Cardiomyopathies / pathology
-
Cardiotoxicity / etiology
-
Cell Adhesion / drug effects
-
Cell Degranulation / drug effects
-
Cells, Cultured
-
Chemokine CXCL10 / metabolism
-
Chemokine CXCL9 / metabolism
-
Disease Models, Animal*
-
Dogs
-
Doxorubicin* / adverse effects
-
Female
-
Fibroblasts / drug effects
-
Fibroblasts / metabolism
-
Fibroblasts / pathology
-
Fibrosis* / chemically induced
-
Granzymes / metabolism
-
Humans
-
Interferon-gamma* / metabolism
-
Lymphocyte Activation / drug effects
-
Male
-
Mice
-
Mice, Inbred C57BL
-
Myocardium / immunology
-
Myocardium / metabolism
-
Myocardium / pathology
-
Receptors, CXCR3 / metabolism
-
Systole / drug effects
-
T-Lymphocytes, Cytotoxic* / drug effects
-
T-Lymphocytes, Cytotoxic* / immunology
-
Ventricular Function, Left / drug effects
Substances
-
Doxorubicin
-
Interferon-gamma
-
Antibiotics, Antineoplastic
-
Receptors, CXCR3
-
Chemokine CXCL10
-
Granzymes
-
CXCR3 protein, human
-
Gzmb protein, mouse
-
Chemokine CXCL9
-
IFNG protein, mouse
-
CXCL10 protein, human
-
IFNG protein, human
Grants and funding
-
HL162200/U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
-
HL159907A/U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
-
NIH R01 HL163172/U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
-
Springboard Tier 1/Tufts University
-
HL144477/U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
-
906361/American Heart Association (American Heart Association, Inc.)
-
3R01HL144477-04S1/U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
-
NIH K08 HL145019/U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
-
906561/American Heart Association (American Heart Association, Inc.)
-
HL165725/U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
-
NIH U01CA272268/U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)